Upstream Bio (NASDAQ:UPB) Trading 14.4% Higher – Should You Buy?

Shares of Upstream Bio, Inc. (NASDAQ:UPB) shot up 14.4% during trading on Wednesday . The company traded as high as $9.35 and last traded at $9.29. 732,969 shares were traded during mid-day trading, a decline of 47% from the average session volume of 1,395,897 shares. The stock had previously closed at $8.12.

Analyst Upgrades and Downgrades

A number of research analysts recently weighed in on the stock. Lifesci Capital initiated coverage on shares of Upstream Bio in a research report on Tuesday, December 2nd. They issued an “outperform” rating and a $43.00 target price for the company. Evercore started coverage on Upstream Bio in a research report on Tuesday, November 18th. They set an “outperform” rating and a $40.00 price target for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Upstream Bio in a research report on Wednesday, January 21st. Finally, Mizuho upgraded Upstream Bio to a “strong-buy” rating in a research note on Thursday, December 18th. One research analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating and one has issued a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus price target of $45.25.

Upstream Bio Trading Up 14.1%

The firm’s 50 day moving average price is $21.12 and its two-hundred day moving average price is $22.23. The company has a market capitalization of $500.63 million, a price-to-earnings ratio of -4.92 and a beta of 2.96.

Institutional Trading of Upstream Bio

Institutional investors and hedge funds have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in shares of Upstream Bio during the 4th quarter worth approximately $29,000. Torren Management LLC bought a new position in Upstream Bio during the fourth quarter worth $30,000. Empowered Funds LLC acquired a new position in shares of Upstream Bio in the fourth quarter valued at $45,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Upstream Bio in the fourth quarter valued at $71,000. Finally, Russell Investments Group Ltd. raised its position in shares of Upstream Bio by 1,963.9% in the third quarter. Russell Investments Group Ltd. now owns 3,034 shares of the company’s stock valued at $57,000 after purchasing an additional 2,887 shares during the period.

Upstream Bio Company Profile

Upstream Bio, Inc is a clinical-stage biotechnology company focused on the development of next-generation prophylactic vaccines and immuno-oncology therapies. Leveraging a proprietary viral vector platform, the company aims to deliver optimized antigen payloads that stimulate robust and durable immune responses against both infectious diseases and cancer targets. Upstream Bio’s approach emphasizes safety, manufacturability and potential for rapid scale-up to address emerging public health challenges.

The company’s research and development pipeline includes multiple viral vector-based candidates in early clinical and preclinical stages.